C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Contrasting Results of PANAMO and FORCE

Crit Care Med. 2023 May 1;51(5):e129-e130. doi: 10.1097/CCM.0000000000005796. Epub 2023 Apr 13.

Authors

Julien Carvelli^{1

2

3}, Eric Vivier^{2

3

4

5}

Affiliations

¹ Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Réanimation des Urgences, Marseille, France.
² Aix Marseille Univ, Marseille, France.
³ Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Immunology, Marseille Immunopole, Marseille, France.
⁴ Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France.
⁵ Innate Pharma, Marseille, France.

PMID: 37052450
DOI: 10.1097/CCM.0000000000005796

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Letter
Comment

MeSH terms

Animals
COVID-19*
Complement C5a
Humans
Mice
Mice, Knockout
Receptor, Anaphylatoxin C5a
Signal Transduction

Substances

Complement C5a
Receptor, Anaphylatoxin C5a
C5ar1 protein, mouse